- Home
- AGI vs NBIX Comparison
AGI vs NBIX Comparison
Compare AGI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGI | NBIX |
|---|---|---|
| Founded | 2003 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 14.4B |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AGI | NBIX |
|---|---|---|
| Price | $35.91 | $155.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 19 |
| Target Price | $41.00 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 2.6M | 969.9K |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 112.89 | 12.44 |
| EPS | 1.28 | ★ 4.19 |
| Revenue | $1,609,300,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | $40.10 | $23.76 |
| Revenue Next Year | $33.02 | $18.01 |
| P/E Ratio | ★ $28.05 | $37.10 |
| Revenue Growth | ★ 31.30 | 19.61 |
| 52 Week Low | $17.80 | $84.23 |
| 52 Week High | $38.00 | $157.67 |
Technical Indicators
Market Signals| Indicator | AGI | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 64.81 |
| Support Level | $35.44 | $150.26 |
| Resistance Level | $38.00 | $154.35 |
| Average True Range (ATR) | 1.36 | 4.16 |
| MACD | 0.21 | 1.07 |
| Stochastic Oscillator | 68.68 | 93.25 |
Price Performance
Historical ComparisonAbout AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.